Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents - PubMed (original) (raw)
Comparative Study
Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents
Timothy E Wilens et al. Arch Pediatr Adolesc Med. 2008 Oct.
Abstract
Objective: To examine the effects of early stimulant treatment on subsequent risk for cigarette smoking and substance use disorders (SUDs) in adolescents with attention-deficit/hyperactivity disorder (ADHD).
Design: Case-controlled, prospective, 5-year follow-up study.
Setting: Massachusetts General Hospital, Boston.
Participants: Adolescents with and without ADHD from psychiatric and pediatric sources. Blinded interviewers determined all diagnoses using structured interviews. Intervention Naturalistic treatment exposure with psychostimulants for ADHD.
Main outcome measures: We modeled time to onset of SUDs and smoking as a function of stimulant treatment.
Results: We ascertained 114 subjects with ADHD (mean age at follow-up, 16.2 years) having complete medication and SUD data; 94 of the subjects were treated with stimulants. There were no differences in SUD risk factors between naturalistically treated and untreated groups other than family history of ADHD. We found no increased risks for cigarette smoking or SUDs associated with stimulant therapy. We found significant protective effects of stimulant treatment on the development of any SUD (hazard ratio [HR], 0.27; 95% confidence interval [CI], 0.13-0.60; chi(2)(113) = 10.57, P = .001) and cigarette smoking (HR, 0.28; 95% CI, 0.14-0.60; chi(2)(111) = 10.05, P = .001) that were maintained when controlling for conduct disorder. We found no effects of time to onset or duration of stimulant therapy on subsequent SUDs or cigarette smoking in subjects with ADHD.
Conclusion: Stimulant therapy does not increase but rather reduces the risk for cigarette smoking and SUDs in adolescents with ADHD.
Figures
Figure 1
The effects of prior stimulant exposure on risk for a subsequent substance use disorder (SUD; curves truncated at 18 years).
Figure 2
The effects of prior stimulant exposure on risk for a subsequent cigarette smoking (dependence; curves truncated at 18 years).
Similar articles
- A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults.
Faraone SV, Biederman J, Wilens TE, Adamson J. Faraone SV, et al. Psychol Med. 2007 Dec;37(12):1743-52. doi: 10.1017/S0033291707000335. Epub 2007 Mar 12. Psychol Med. 2007. PMID: 17349106 - A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.
Kollins SH. Kollins SH. Curr Med Res Opin. 2008 May;24(5):1345-57. doi: 10.1185/030079908x280707. Epub 2008 Apr 1. Curr Med Res Opin. 2008. PMID: 18384709 Review. - Does ADHD predict substance-use disorders? A 10-year follow-up study of young adults with ADHD.
Wilens TE, Martelon M, Joshi G, Bateman C, Fried R, Petty C, Biederman J. Wilens TE, et al. J Am Acad Child Adolesc Psychiatry. 2011 Jun;50(6):543-53. doi: 10.1016/j.jaac.2011.01.021. Epub 2011 Apr 22. J Am Acad Child Adolesc Psychiatry. 2011. PMID: 21621138 Free PMC article. - ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood - a naturalistic long-term follow-up study.
Dalsgaard S, Mortensen PB, Frydenberg M, Thomsen PH. Dalsgaard S, et al. Addict Behav. 2014 Jan;39(1):325-8. doi: 10.1016/j.addbeh.2013.09.002. Epub 2013 Sep 10. Addict Behav. 2014. PMID: 24090624 - When ADHD and substance use disorders intersect: relationship and treatment implications.
Wilens TE, Fusillo S. Wilens TE, et al. Curr Psychiatry Rep. 2007 Oct;9(5):408-14. doi: 10.1007/s11920-007-0053-3. Curr Psychiatry Rep. 2007. PMID: 17915081 Review.
Cited by
- Stimulant medication and substance use outcomes: a meta-analysis.
Humphreys KL, Eng T, Lee SS. Humphreys KL, et al. JAMA Psychiatry. 2013 Jul;70(7):740-9. doi: 10.1001/jamapsychiatry.2013.1273. JAMA Psychiatry. 2013. PMID: 23754458 Free PMC article. - Approche diagnostique et de prise en charge du trouble déficitaire de l’attention avec hyperactivité chez l’enfant.
Jerome D, Jerome L. Jerome D, et al. Can Fam Physician. 2020 Oct;66(10):e255-e260. Can Fam Physician. 2020. PMID: 33077465 Free PMC article. Review. French. - The Risk of Methylphenidate Pharmacotherapy for Adults with ADHD.
Bieś R, Fojcik J, Warchala A, Trędzbor B, Krysta K, Piekarska-Bugiel K, Krzystanek M. Bieś R, et al. Pharmaceuticals (Basel). 2023 Sep 13;16(9):1292. doi: 10.3390/ph16091292. Pharmaceuticals (Basel). 2023. PMID: 37765100 Free PMC article. Review. - Executive cognitive dysfunction and ADHD in cocaine dependence: searching for a common cognitive endophenotype for addictive disorders.
Cunha PJ, Gonçalves PD, Ometto M, Dos Santos B, Nicastri S, Busatto GF, de Andrade AG. Cunha PJ, et al. Front Psychiatry. 2013 Oct 21;4:126. doi: 10.3389/fpsyt.2013.00126. eCollection 2013. Front Psychiatry. 2013. PMID: 24155725 Free PMC article. - Risk-Taking Behavior in Attention Deficit/Hyperactivity Disorder (ADHD): a Review of Potential Underlying Mechanisms and of Interventions.
Pollak Y, Dekkers TJ, Shoham R, Huizenga HM. Pollak Y, et al. Curr Psychiatry Rep. 2019 Mar 22;21(5):33. doi: 10.1007/s11920-019-1019-y. Curr Psychiatry Rep. 2019. PMID: 30903380 Review.
References
- Polanczyk G, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942–8. - PubMed
- Hinshaw SP. Preadolescent girls with attention-deficit/hyperactivity disorder: I. Background characteristics, comorbidity, cognitive, and social functioning, and parenting practices. J Consult Clin Psych. 2002;70(5):1086–1098. - PubMed
- Biederman J, et al. Psychopathology in females with attention-deficit/hyperactivity disorder: A controlled, five-year prospective study. Biological Psychiatry. 2006;60(10):1098–105. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- DA R01 DA14419/DA/NIDA NIH HHS/United States
- R01 DA014419-05/DA/NIDA NIH HHS/United States
- R01 DA014419/DA/NIDA NIH HHS/United States
- K24 DA016264-05/DA/NIDA NIH HHS/United States
- K24 DA016264-06A1/DA/NIDA NIH HHS/United States
- K24 DA016264/DA/NIDA NIH HHS/United States